Eve Gallop‐Evans - Concepedia

Author

Eve Gallop‐Evans

Velindre Cancer Centre

Also Known As

E Gallop-Evans, E. Gallop-Evans, E. Gallop‐Evans, Eve Gallop-Evans, Eve Gallop‐Evans, I. Fotina, Kate Fife

Publications

1.6K

Citations

H-Index

Concepts

All Affiliations

Velindre Cancer Centre Cancer Research UK University of Manchester The Christie NHS Foundation Trust GlaxoSmithKline (United States)

About

Eve Gallop‐Evans is an author at Velindre Cancer Centre specializing in radiation oncology, medicine, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	4	4	576
2	Health Sciences	1	1	104
3	Public Health	1	1	82
4	Obstetrics	1	1	82
5	Pathology	1	1	152

Eve Gallop‐Evans

Publications

1.1K

Citations

H-Index

Page 1

	Year	Citations
4 Gy versus 24 Gy radiotherapy for patients with indolent lymphoma (FORT): a randomised phase 3 non-inferiority trial Peter Hoskin, Amy A. Kirkwood, Bilyana Popova, The Lancet Oncology Lymphoid NeoplasiaSurgical OncologyRadiation TherapyMedicineGy Versus 24	2014	238
Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): secondary analysis of a randomised, phase 3 trial Judith Trotman, Sally F. Barrington, David Belada, The Lancet Oncology Lymphoid NeoplasiaEnd-of-induction Pet ResponseMedicinePrognostic ValueFollicular Lymphoma	2018	152
Ofatumumab monotherapy in rituximab-refractory follicular lymphoma: results from a multicenter study Myron S. Czuczman, Luis Fayad, Vincent Delwail, Blood	2012	125
Association of early disease progression and very poor survival in the GALLIUM study in follicular lymphoma: benefit of obinutuzumab in reducing the rate of early progression John F. Seymour, Robert Marcus, Andrew Davies, Haematologica	2018	109
4 Gy versus 24 Gy radiotherapy for follicular and marginal zone lymphoma (FoRT): long-term follow-up of a multicentre, randomised, phase 3, non-inferiority trial Peter Hoskin, B. Popova, Oliver Schofield, The Lancet Oncology Lymphoid NeoplasiaGy RadiotherapySurgical OncologyRadiation TherapyGy Versus 24	2021	104
U.K. consensus statement on safe clinical prescribing of bexarotene for patients with cutaneous T-cell lymphoma Julia Scarisbrick, Stephen Morris, Richard Azurdia, British Journal of Dermatology	2012	101
Five Years' Experience Treating Locally Advanced Cervical Cancer With Concurrent Chemoradiotherapy and High-Dose-Rate Brachytherapy: Results From a Single Institution Kate Parker, Eve Gallop‐Evans, Louise Hanna, International Journal of Radiation OncologyBiologyPhysics Concurrent ChemoradiotherapyCervical Cancer ManagementCervical CancerRadiation TherapyMedicine	2008	82
Correlates of fertility issues in an Internet survey of cancer survivors Sibil Tschudin, Laura Bunting, Jacinta Abraham, Journal of Psychosomatic Obstetrics & Gynecology	2010	56
A multicentre, phase <scp>II</scp> trial of ofatumumab monotherapy in relapsed/progressive diffuse large B‐cell lymphoma Bertrand Coiffier, John Radford, André Bosly, British Journal of Haematology	2013	42
Evaluation of Ofatumumab, a Novel Human CD20 Monoclonal Antibody, as Single Agent Therapy in Rituximab-Refractory Follicular Lymphoma. Anton Hagenbeek, Luis Fayad, Vincent Delwail, Blood	2009	41

Page 1